February 20, 2018 / 11:41 AM / 4 months ago

BRIEF-Neotract Announces FDA Clearance Of Expanded Indications For Urolift System

* NEOTRACT ANNOUNCES FDA CLEARANCE OF EXPANDED INDICATIONS FOR UROLIFT® SYSTEM

* NEOTRACT - EXPANDED INDICATIONS MEAN PATIENTS WITH OBSTRUCTIVE MEDIAN LOBE, AS YOUNG AS 45 NOW ELIGIBLE TO GET TREATMENT WITH UROLIFT FOR BPH SYMPTOMS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below